Abstract
Hypoxia-inducible factor-1 (HIF-1) is a nuclear transcription factor that is upregulated in hypoxia and coordinates the adaptive response to hypoxia by driving the expression of over 100 genes. In facilitating tissues to adapt to hypoxia, HIF-1 may have a role in reducing the cellular damage induced by ischaemia, such as that seen in peripheral arterial disease (PAD), or following acute ischaemic insults such as stroke and myocardial infarction. This therefore raises the possibility of HIF-1 modulation in such contexts to reduce the consequences of ischaemic injury. HIF1 has further been implicated in the pathogenesis of atherosclerosis, abdominal aortic aneurysm (AAA) formation, pulmonary hypertension and systemic hypertension associated with obstructive sleep apnoea. Through a better understanding of the role of HIF-1 in these disease processes, novel treatments which target HIF-1 pathway may be considered. This review summarises the role of HIF-1 in arterial disease, specifically its role in atherosclerosis, ischaemic heart disease, in-stent restenosis following coronary revascularisation, stroke, PAD, AAA formation, pulmonary artery hypertension and systemic hypertension. The potential for exploiting the HIF-1 signalling pathway in developing therapeutics for these conditions is discussed, including progress made so far, with attention given to studies looking into the use of prolyl-hydroxylase inhibitors.
Keywords: Aortic aneurysm, arterial disease, atherosclerosis, hypertension, hypoxia-inducible factor, ischaemic heart disease, prolyl-hydroxylase inhibitor, stroke, angiogenesis, hypoxia-inducible factor-1, obstructive sleep apnea
Current Vascular Pharmacology
Title: Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Volume: 9 Issue: 3
Author(s): Veeru Kasivisvanathan, Joseph Shalhoub, Chung S. Lim, Amanda C. Shepherd, Ankur Thapar and Alun H. Davies
Affiliation:
Keywords: Aortic aneurysm, arterial disease, atherosclerosis, hypertension, hypoxia-inducible factor, ischaemic heart disease, prolyl-hydroxylase inhibitor, stroke, angiogenesis, hypoxia-inducible factor-1, obstructive sleep apnea
Abstract: Hypoxia-inducible factor-1 (HIF-1) is a nuclear transcription factor that is upregulated in hypoxia and coordinates the adaptive response to hypoxia by driving the expression of over 100 genes. In facilitating tissues to adapt to hypoxia, HIF-1 may have a role in reducing the cellular damage induced by ischaemia, such as that seen in peripheral arterial disease (PAD), or following acute ischaemic insults such as stroke and myocardial infarction. This therefore raises the possibility of HIF-1 modulation in such contexts to reduce the consequences of ischaemic injury. HIF1 has further been implicated in the pathogenesis of atherosclerosis, abdominal aortic aneurysm (AAA) formation, pulmonary hypertension and systemic hypertension associated with obstructive sleep apnoea. Through a better understanding of the role of HIF-1 in these disease processes, novel treatments which target HIF-1 pathway may be considered. This review summarises the role of HIF-1 in arterial disease, specifically its role in atherosclerosis, ischaemic heart disease, in-stent restenosis following coronary revascularisation, stroke, PAD, AAA formation, pulmonary artery hypertension and systemic hypertension. The potential for exploiting the HIF-1 signalling pathway in developing therapeutics for these conditions is discussed, including progress made so far, with attention given to studies looking into the use of prolyl-hydroxylase inhibitors.
Export Options
About this article
Cite this article as:
Kasivisvanathan Veeru, Shalhoub Joseph, S. Lim Chung, C. Shepherd Amanda, Thapar Ankur and H. Davies Alun, Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495602
DOI https://dx.doi.org/10.2174/157016111795495602 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery Leptin and Vascular Smooth Muscle Cells
Current Pharmaceutical Design Cigarette Smoking in Methadone Maintained Patients: An Up-to-Date Review
Current Drug Abuse Reviews Metabolic Effects of a Diet with Inulin-Enriched Pasta in Healthy Young Volunteers
Current Pharmaceutical Design Preface
Current Nutrition & Food Science T Cell Homeostasis in Centenarians: From the Thymus to the Periphery
Current Pharmaceutical Design Inhibitors of Mammalian Acetyl-CoA Carboxylase
Recent Patents on Cardiovascular Drug Discovery Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology New Insight in Antiplatelet Therapy Monitoring in Cardiovascular Patients: From Aspirin to Thienopyridine
Cardiovascular & Hematological Disorders-Drug Targets Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Suppression of Virulence of Porphyromonas gingivalis by Potent Inhibitors Specific for Gingipains
Current Protein & Peptide Science Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Reproductive Effects of Low-to-Moderate Medical Radiation Exposure
Current Medicinal Chemistry Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety AMPK Activators as Novel Therapeutics for Type 2 Diabetes
Current Topics in Medicinal Chemistry Diet Effects on Atherosclerosis in Mice
Current Drug Targets